Table 1 Demographics and tumor characteristics

Age at diagnosis, median (range)

52 years (25–85)

52 (26–85)

50 (27–73)

50 (31–84)

 ≤50 years

75

(46.9%)

33

(44.0%)

23

(50.0%)

19

(52.8%)

0.64

 >50 years

85

(53.1%)

42

(56.0%)

23

(50.0%)

17

47.2%)

Race/ethnicity

 White, non-Hispanic

59

(36.9%)

29

(38.7%)

19

(41.3%)

9

(25.0%)

0.29

 Black, non-Hispanic

27

(16.9%)

10

(13.3%)

7

(15.2%)

10

(27.8%)

 Hispanic

44

(27.5%)

18

(24.0%)

14

(30.4%)

11

(30.6%)

 Other or unknown

30

(18.8%)

18

(24.0%)

6

(13.0%)

6

(16.7%)

Laterality

 Left

80

(50.0%)

42

(56.0%)

20

(43.4%)

17

(47.2%)

0.42

 Right

79

(49.4%)

33

(44.0%)

25

(54.3%)

19

(52.8%)

 Bilateral

1

(0.6%)

0

(0%)

1

(2.2%)

0

(0%)

Pathology

 IDC

128

(80.0%)

52

(69.3%)

40

(87.0%)

33

(91.7%)

0.02

 ILC

15

(9.4%)

13

(17.3%)

1

(2.2%)

1

(2.8%)

 Mixed

14

(8.8%)

8

(10.7%)

5

(10.9%)

1

(2.8%)

 Other

3

(1.9%)

2

(2.7%)

0

(0%)

1

(2.8%)

Chemotherapy

 chemo (AC/T backbone)

100

(62.5%)

46

(61.3%)

25

(54.3%)

28

(77.8%)

0.04*

 non-AC/T backbone

50

(31.2%)

23

(30.7%)

20

(43.4%)

6

(16.7%)

 Unspecified

10

(6.2%)

6

(8.0%)

1

(2.2%)

2

(5.6%)

Trastuzumab received

37 of 46

(80.4%)

N/A

37 of 46

(80.4%)

N/A

N/A

Surgery

 Mastectomy

114

(71.3%)

59

(78.7%)

32

(69.6%)

22

(61.1%)

0.23

 Lumpectomy

44

(27.5%)

15

(20.0%)

14

(30.4%)

14

(38.9%)

 ALND only^a

2

(1.3%)

1

(1.3%)

0

(0%)

0

(0%)

Radiation

 Breast only (2 fields)

19

(11.9%)

7

(9.3%)

6

(13.0%)

6

(16.7%)

0.51

 CW/breast + axillary + SCV LNs (3 or 4 fields)

112

(70.0%)

52

(69.3%)

32

(69.6%)

25

(69.4%)

 CW/breast + axillary + SCV + IMN (deep tangents or 5 fields or IMRT)

13

(8.1%)

5

(6.7%)

4

(8.7%)

4

(11.1%)

 Unspecified

16

(10.0%)

11

(14.7%)

4

(8.7%)

1

(2.8%)

 Boost to tumor cavity and/or scar

91

(56.9%)

43

(57.3%)

21

(45.6%)

27

(75.0%)

0.03

Stage (clinical)

 I

0

(0%)

0

(0%)

0

(0%)

0

(0%)

0.46*

 II

78

(48.8%)

38

(50.7%)

19

(41.3%)

20

(55.6%)

 III

71

(44.3%)

31

(41.3%)

23

(50.0%)

15

(41.7%)

 IV^b

3

(1.9%)

1

(1.3%)

2

(4.3%)

0

(0%)

 Unknown

8

(5.0%)

5

(6.7%)

2

(4.3%)

1

(2.8%)

Stage (pathologic)

 pCR (total)

25

(15.6%)

4

(5.3%)

12

(26.1%)

9

(25.0%)

0.001

 T0

19

(11.9%)

4

(5.3%)

8

(17.4%)

6

(16.7%)

 Tis

6

(3.7%)

0

(0%)

4

(8.7%)

3

(8.3%)

 I

25

(15.6%)

8

(10.7%)

10

(21.7%)

7

(19.4%)

0.07*

 II

49

(30.6%)

26

(34.7%)

10

(21.7%)

12

(33.3%)

 III

59

(36.9%)

37

(49.3%)

12

(26.1%)

8

(22.2%)

 IV

1

(0.6%)

0

(0%)

1

(2.2%)

0

(0%)

 Unknown

1

(0.6%)

0

(0%)

1

(2.2%)

0

(0%)